- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02409576
Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (NKEXPSARC)
Progress in the treatment of children with leukemia and lymphoma results in high cure rates but progress in the treatment of children and adolescents with solid tumors has been slow. Despite aggressive therapy with multimodality treatment involving surgery, radiation and chemotherapy, about two thirds of the patients with metastatic Ewing sarcoma (EWS), and intermediate and high risk rhabdomyosarcoma (RMS) will relapse. The available second line therapies for relapse are limited and often not effective. There is a dire need to look for treatment options beyond conventional means for the treatment of these patients.
Infusions of allogeneic natural killer (NK) cells in leukemia patients have shown to be tolerated well without inducing graft versus host disease (GVHD). There is also mounting evidence that NK cells have activity against solid tumors.
In the lab the investigators tested NK cell activity against cell lines from different paediatric solid tumors. Among paediatric solid tumors, EWS and RMS are exquisitely sensitive to killing by expanded NK cells; NK cells also have activity against OS cells. Preliminary clinical data suggest that donor NK cells may exert antitumor activity in children with solid tumors undergoing allogeneic hematopoietic stem cell transplantation.
Taking into account the safety of adaptive NK cell infusion, and their efficacy against EWS, RMS and OS, NK cells could be a powerful new tool in the treatment of paediatric solid tumors.
The great anti-tumor activity of expanded and activated NK cells, together with the feasibility of infusing haploidentical NK cells in a non-transplant setting form a compelling rationale for the clinical testing of these NK cells in patients with sarcoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Adoptive transfer of allogeneic NK cells has been shown to be safe in patients with leukemia.
The patients enrolled on this will receive lymphodepleting chemotherapy with cyclophosphamide (1 day) followed by fludarabine (5 days) Each patient will receive IL-2 on alternate days starting 1 day before infusion of NK cells for a total of 6 doses.
Patient will undergo imaging MRI or PET or CT scan one month after the infusion to assess response to the NK cell infusion.
In our study we aim to determine the feasibility, safety and efficacy of expanded, activated NK cells in patients with EWS and RMS .
We will also study the persistence and phenotype of expanded NK cells in research participants with EWS and RMS .
The main hypothesis to be tested in this study is that infusion of expanded, activated haploidentical NK cells can produce measurable clinical responses in patients with EWS and RMS .
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Bernice Oh Lingzhi, MBBS
- Phone Number: (65)97739114
- Email: bernice_lx_oh@nuhs.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 119228
- Recruiting
- National University Hospital
-
Contact:
- Bernice Oh
- Phone Number: (65) 97739114
- Email: bernice_lx_oh@nuhs.edu.sg
-
Contact:
- Clarice Chan
- Phone Number: (65) 67726586
- Email: chan_zi_ying_clarice@nuhs.edu.sg
-
Principal Investigator:
- Bernice Oh
-
Sub-Investigator:
- Dario Campana
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A ) NK cell Recipient:
- Age 0 months to 80 years old.
Patients with metastatic, progressive or relapsed EWS, RMS after completing standard of care therapy who are at high risk of relapse even if they do not have any evidence of residual disease.
a) For patients without residual disease at the point of study entry, response to NK cells will be measured by their incidence of relapse as indicated by their 5-year event free survival. Only patients at high risk of relapse > 70% will be enrolled if there is no evidence of residual disease.
- Shortening fraction greater than or equal to 25%. Left ventricular ejection fraction (LVEF) greater than or equal to 40%
- Glomerular filtration rate greater than or equal to 60 ml/min/1.73 m2.
- Pulse oximetry greater than or equal to 92% on room air.
- Direct bilirubin less than or equal to 3.0 mg/dL (50 mmol/L).
- Alanine aminotransferase (ALT) is no more than 2 times the upper limit of normal.
- Aspartate transaminases (AST) is no more than 2 times the upper limit of normal.
- Karnofsky or Lansky performance score of greater than or equal to 50.
- Does not have a current pleural or pericardial effusion.
- Has a suitable adult family member donor available for NK cell donation.
- Has recovered from all acute NCI Common Terminology Criteria for Adverse Events (CTCAE) grade II-IV non-hematologic acute toxicities resulting from prior therapy per the judgment of the PI.
- At least two weeks since receipt of any biological therapy, systemic chemotherapy, and/or radiation therapy.
- Is not receiving more than the equivalent of prednisone 10 mg daily.
- Not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment).
- Not lactating.
B) NK cell Donor:
- First and second degree relative acceptable.
- 18 years of age or above.
- Not lactating.
- Greater than or equal to 3 of 6 HLA match to recipient.
- Meets eligibility and suitability criteria for hematopoietic cells donation as per institutional guidelines.
- Not pregnant (negative serum or urine pregnancy test to be conducted within 7 days prior to enrollment).
- HIV negative. Negative results must be within 60 days prior to enrolment.
Exclusion Criteria:
Failure to meet any of the inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Expanded, activated NK Cells(NKEXPSARC)
Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease response after expanded activated NK cell infusion
Time Frame: 1 month post-NK cell infusion (and at regular intervals thereafter till a year post-NK cell infusion)
|
Radiological response will be measured based on PET or MRI or CT scan whichever is appropriate imaging for the tumor type and location.
|
1 month post-NK cell infusion (and at regular intervals thereafter till a year post-NK cell infusion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence and phenotype of expanded NK cells in research participants with EWS, RMS and OS.
Time Frame: 1 month ( 30 days) post- NK cell infusion
|
NK cell persistence and phenotype will be monitored weekly upto 4 weeks post infusion from peripheral blood.
|
1 month ( 30 days) post- NK cell infusion
|
Toxicity of NK cells infusion (NCI toxicity criteria CTC version 4.0)
Time Frame: 1 month ( 30 days) post- NK cell infusion
|
Patients will be monitored for toxicity based on NCI toxicity criteria CTC version 4.0
|
1 month ( 30 days) post- NK cell infusion
|
Performance status will be assessed by age-dependent Performances Scores ( Lansky scale or Karnofsky performance scale)
Time Frame: Initiation of conditioning till 30 days post-NK cell infusion
|
Patients performance status will be monitored using Lansky scale for patients below 16 years of age and Karnofsky performance scale for patients more than 16 years of age.
|
Initiation of conditioning till 30 days post-NK cell infusion
|
Acute and Chronic GVHD
Time Frame: Initiation of conditioning until 1 month ( 30 days) post- last dose of IL-2
|
Patients will monitored for clinical evidence of GVHD
|
Initiation of conditioning until 1 month ( 30 days) post- last dose of IL-2
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bernice Oh, Department of Paediatrics, National University Hospital
- Principal Investigator: Dario Campana, Department of Paediatrics, National University of Singapore
Publications and helpful links
General Publications
- Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010 Aug 1;16(15):3901-9. doi: 10.1158/1078-0432.CCR-10-0735. Epub 2010 Jun 11.
- Perez-Martinez A, de Prada Vicente I, Fernandez L, Gonzalez-Vicent M, Valentin J, Martin R, Maxwell H, Sevilla J, Vicario JL, Diaz MA. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012 Nov;40(11):882-891.e1. doi: 10.1016/j.exphem.2012.07.004. Epub 2012 Jul 4.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSRB 2014/00452
- CTC1400413 (NUH) (Other Identifier: Health Sciences Authority; Singapore)
- CTC1400412 (KKWCH) (Other Identifier: Health Sciences Authority ; Singapore)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ewing Sarcoma
-
University of OxfordAstellas Pharma Inc; European Organisation for Research and Treatment of Cancer... and other collaboratorsCompletedRefractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited Kingdom, Germany, Netherlands, Italy, France
-
Jazz PharmaceuticalsRecruitingEwing Sarcoma | Refractory Ewing Sarcoma | Relapsed Ewing SarcomaUnited States, Canada
-
Dana-Farber Cancer InstituteCompletedRefractory Ewing Sarcoma | Refractory Osteosarcoma | Relapsed Ewing Sarcoma | Relapsed OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Ewing Sarcoma | Metastatic Ewing SarcomaUnited States
-
Incyte CorporationTerminatedRelapsed Ewing SarcomaUnited States, Spain, United Kingdom, Italy
-
Memorial Sloan Kettering Cancer CenterRecruitingNewly Diagnosed Ewing SarcomaUnited States
-
Italian Sarcoma GroupRecruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaS. Anna HospitalUnknownSoft Tissue Sarcoma | EwingItaly
-
Institut CurieUNICANCERCompletedEwing Sarcoma Family of TumorsFrance
-
Istituto Ortopedico RizzoliRegione Emilia-RomagnaCompletedEwing Sarcoma Family of TumorsUnited Kingdom, Italy
Clinical Trials on Expanded , Activated NK cells
-
Peking University People's HospitalRecruitingTransplantation Infection | CMV ViremiaChina
-
Belarusian Research Center for Pediatric Oncology...RecruitingAcute Myeloid LeukemiaBelarus
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Solving Kids' Cancer; Wade's Army; Midwest Athletes... and other collaboratorsWithdrawnOsteosarcoma | Neuroblastoma | Recurrent Neuroblastoma | Relapsed NeuroblastomaUnited States
-
Hospital Universitario La PazCompletedRelapsed/Refractory Paediatric Acute LeukaemiaSpain
-
Xcyte TherapiesCompletedChronic Lymphocytic LeukemiaUnited States
-
Xcyte TherapiesUnknownMultiple MyelomaUnited States
-
Xuanwu Hospital, BeijingUnknownBreast Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Colon CancerChina
-
University Hospital, Basel, SwitzerlandCompleted
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown